Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
NCT ID: NCT00841828
Last Updated: 2023-03-31
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
102 participants
Study Classification
INTERVENTIONAL
Study Start Date
2009-02-28
Study Completion Date
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Phase II randomized multicenter trial to compare Epirubicin and Cyclophosphamide plus Docetaxel and Trastuzumab with Epirubicin and Cyclophosphamide plus Docetaxel and Lapatinib for patients with positive HER2 and resectable or locally advanced breast cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
NCT00524303
Neoplasms, Breast
COMPLETED
PHASE2
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
NCT00667251
Breast Cancer
COMPLETED
PHASE3
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
NCT00021255
Breast Neoplasms
COMPLETED
PHASE3
Lapatinib and Trastuzumab With or Without Endocrine Therapy
NCT00548184
Breast Cancer
COMPLETED
PHASE2
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
NCT02238509
Metastatic Breast Cancer
UNKNOWN
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a multicenter, open label, randomized phase II trial. Women with primary cancer and overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) who have not received prior treatment for invasive breast cancer will be included. The study will analyze the efficacy and tolerance of Lapatinib and Docetaxel and the Trastuzumab and Docetaxel after 4 cycles of Epirubicin and Cyclophosphamide in patients with breast cancer HER2 positive.
102 patients will be stratified according to tumor size and estrogen receptor status (positive or negative) to be randomized to receive one of the following treatment arms:
* Experimental arm: Epirubicin 90mg/m2 in combination with cyclophosphamide 600mg/m2 intravenous (IV) every 21 days for 4 cycles, followed by oral Lapatinib 1250mg once a day plus docetaxel 100mg/m2 IV every 21 days for 4 cycles with the administration of granulocyte-colony stimulating factor (G-CSF) between days 2 and 7 or on day +1 according to the G-CSF used by the site.
* Control arm: Epirubicin 90mg/m2 in combination with cyclophosphamide 600mg/m2 IV every 21 days for 4 cycles, followed by a loading dose of Trastuzumab 8mg/kg IV followed by Trastuzumab 6mg/kg IV every 3 weeks plus docetaxel 100mg/m2 IV every 21 days for 4 cycles with the administration of G-CSF between days 2 and 7 or on day +1 according to the G-CSF used by the site.
Treatment duration: The patients will be in treatment for an average of 6 months for both arms.
Study population: Patients with operable or locally advanced breast cancer, HER2 positive who are candidates to receive neoadjuvant treatment and who have not received pre-treatment for invasive breast cancer.
Population in study and number total of patients:
The aim is to determine if neoadjuvant treatment with selective therapy can increase the complete pathological response (pCR) in breast cancer by the determination of molecular markers in the tumoral sample before treatment. Then, and between 3 and 4 weeks after the last administration of Docetaxel, and 24 hours after the administration of Lapatinib, surgery will be performed and in the surgical sample will be determined the molecular markers analyzed before of the treatment in the tumor sample.
Patients with HER2 positive, defined as immunohistochemistry 3+ or positive fluorescence in situ hybridization (FISH), will be included. If immunohistochemistry 2+ it will be necessary to confirm the HER2 positive status by FISH. All results will be reevaluated later in the central laboratory.
Statistical consideration: The sample size has been calculated using the 2-stage Simon method and with pathological complete response (pCR) as the primary study end point. Sample size has been based on the null hypothesis of a pCR of 40% and an alternative hypothesis of a pCR of 60%. Assuming an alpha error of 0.05 and a test power of 80%, 92 evaluable patients will be required to be recruited and retained in the study. Sixteen patients per arm will be included in the first stage, for at least eight pCR per arm to be seen, and 30 additional patients per arm will be included in the second stage for a total of 46 evaluable patients in each arm. Assuming a 10% drop-out rate, 102 patients will be recruited.
The objective of the random distribution to treatment arms is to select the most active arm for a subsequent development. It is based on a standard of pCR of 40%, in order to detect an increase in the pCR rate of 60% in both arms, it would be necessary to include 46 patients in each arm (Simon's method in 2 stages (Optimal design)). It has been considered an error a = 0.05 and a power 80% statistics. Therefore, in the first stage it would be necessary to include 16 patients in each arm if we found more than 7 patients with pCR in each arm we will continue including until reaching the 46 in each arm. The results will be significant if we find at least 23 patients with pCR in each arm. Assuming that 10% of patients are not evaluable, the number The total number of patients to be included is 102 patients (51 patients per arm of treatment).
102 patients will be stratified according to tumor size and estrogen receptor status (positive or negative) to be randomized to receive one of the following treatment arms:
* Experimental arm: Epirubicin 90mg/m2 in combination with cyclophosphamide 600mg/m2 intravenous (IV) every 21 days for 4 cycles, followed by oral Lapatinib 1250mg once a day plus docetaxel 100mg/m2 IV every 21 days for 4 cycles with the administration of granulocyte-colony stimulating factor (G-CSF) between days 2 and 7 or on day +1 according to the G-CSF used by the site.
* Control arm: Epirubicin 90mg/m2 in combination with cyclophosphamide 600mg/m2 IV every 21 days for 4 cycles, followed by a loading dose of Trastuzumab 8mg/kg IV followed by Trastuzumab 6mg/kg IV every 3 weeks plus docetaxel 100mg/m2 IV every 21 days for 4 cycles with the administration of G-CSF between days 2 and 7 or on day +1 according to the G-CSF used by the site.
Treatment duration: The patients will be in treatment for an average of 6 months for both arms.
Study population: Patients with operable or locally advanced breast cancer, HER2 positive who are candidates to receive neoadjuvant treatment and who have not received pre-treatment for invasive breast cancer.
Population in study and number total of patients:
The aim is to determine if neoadjuvant treatment with selective therapy can increase the complete pathological response (pCR) in breast cancer by the determination of molecular markers in the tumoral sample before treatment. Then, and between 3 and 4 weeks after the last administration of Docetaxel, and 24 hours after the administration of Lapatinib, surgery will be performed and in the surgical sample will be determined the molecular markers analyzed before of the treatment in the tumor sample.
Patients with HER2 positive, defined as immunohistochemistry 3+ or positive fluorescence in situ hybridization (FISH), will be included. If immunohistochemistry 2+ it will be necessary to confirm the HER2 positive status by FISH. All results will be reevaluated later in the central laboratory.
Statistical consideration: The sample size has been calculated using the 2-stage Simon method and with pathological complete response (pCR) as the primary study end point. Sample size has been based on the null hypothesis of a pCR of 40% and an alternative hypothesis of a pCR of 60%. Assuming an alpha error of 0.05 and a test power of 80%, 92 evaluable patients will be required to be recruited and retained in the study. Sixteen patients per arm will be included in the first stage, for at least eight pCR per arm to be seen, and 30 additional patients per arm will be included in the second stage for a total of 46 evaluable patients in each arm. Assuming a 10% drop-out rate, 102 patients will be recruited.
The objective of the random distribution to treatment arms is to select the most active arm for a subsequent development. It is based on a standard of pCR of 40%, in order to detect an increase in the pCR rate of 60% in both arms, it would be necessary to include 46 patients in each arm (Simon's method in 2 stages (Optimal design)). It has been considered an error a = 0.05 and a power 80% statistics. Therefore, in the first stage it would be necessary to include 16 patients in each arm if we found more than 7 patients with pCR in each arm we will continue including until reaching the 46 in each arm. The results will be significant if we find at least 23 patients with pCR in each arm. Assuming that 10% of patients are not evaluable, the number The total number of patients to be included is 102 patients (51 patients per arm of treatment).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Breast Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental
Epirubicin + Cyclophosphamide -\> Docetaxel + Lapatinib
Group Type
EXPERIMENTAL
Epirubicin
Intervention Type
DRUG
Cyclophosphamide
Intervention Type
DRUG
Docetaxel
Intervention Type
DRUG
Lapatinib
Intervention Type
DRUG
Control
Epirubicin + Cyclophosphamide -\> Docetaxel + Trastuzumab
Group Type
ACTIVE_COMPARATOR
Epirubicin
Intervention Type
DRUG
Cyclophosphamide
Intervention Type
DRUG
Docetaxel
Intervention Type
DRUG
Trastuzumab
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Epirubicin
Intervention Type
DRUG
Cyclophosphamide
Intervention Type
DRUG
Docetaxel
Intervention Type
DRUG
Lapatinib
Intervention Type
DRUG
Trastuzumab
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Ellence
Pharmorubicin
Cytoxan
Neosar
Endoxan
Taxotere
Tykerb
Herceptin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Signature of the written informed consent.
2. Histological documentation of breast cancer.
3. Stage I (T1, N0M0), IIA (T2N0M0); IIB (T2N1M0, T3N0M0), IIIA (TXN2M0) and IIIB (T3N1M0, T4NXM0) primary resectable breast cancer or locally advanced breast cancer.
4. HER2-positive breast cancer, defined as immunohistochemistry (IHQ) 3+ or positive FISH. When IHQ 2+ HER2 status must be assessed by FISH.
5. The patient granted her consent for taking a biopsy before treatment
6. The patient granted her consent for sending two tumor samples to central laboratory for molecular sub study.
7. Two weeks prior randomization pregnancy test negative for women of childbearing potential.
8. Women of childbearing potential must use adequate contraceptive measures during participation into study. Oral, injectable or implant hormonal contraceptives measure are not permitted.
9. A World Health Organization (WHO) performance status of 0 or 1 (Karnofsky ≥ 80)
10. Age \> 18 years.
11. Absence of metastases disease
12. Baseline Electrocardiography (EKG) 12 weeks prior to randomization. Baseline left ventricular ejection fraction (LVEF) value within limit of normal value for the institution or \> 50% of basal value
13. Normal laboratory test 2 weeks prior to randomization:
Haematology values: Neutrophil count ≥ 1,5 x109/l; Platelets ≥ 100 x 109/l; Haemoglobin ≥ 10mg/dl Biochemistry values: serum total bilirubin ≤ 1 x Upper Limit of Normal (ULN); Aspartate aminotransferase (AST) (SGOT) and Alanine aminotransferase (ALT) (SGPT) ≤ 2,5 x ULN; alkaline phosphatase ≤ 5 x ULN. Patients which AST and/or ALT value are \> 1,5 x ULN along with alkaline phosphatase value \> 2,5 x ULN will be not included into the study.
Renal function: serum creatinine ≤ 175 µmol/l (2 mg/dl). If the value is borderline, clearance creatinine must be ≥ 60 ml/min
14. 12 weeks prior to randomization the following assessments and procedures must be fulfilled: Bilateral mammography; Magnetic resonance imaging (MRI) Breast and axillary; Chest X-Ray (posterioanterior and lateral); Abdominal ultrasound; Chest CT-Scan; Abdominal CT-Scan. Bone Scan (if applicable)
15. Patients must be accessible for treatment and follow up
2. Histological documentation of breast cancer.
3. Stage I (T1, N0M0), IIA (T2N0M0); IIB (T2N1M0, T3N0M0), IIIA (TXN2M0) and IIIB (T3N1M0, T4NXM0) primary resectable breast cancer or locally advanced breast cancer.
4. HER2-positive breast cancer, defined as immunohistochemistry (IHQ) 3+ or positive FISH. When IHQ 2+ HER2 status must be assessed by FISH.
5. The patient granted her consent for taking a biopsy before treatment
6. The patient granted her consent for sending two tumor samples to central laboratory for molecular sub study.
7. Two weeks prior randomization pregnancy test negative for women of childbearing potential.
8. Women of childbearing potential must use adequate contraceptive measures during participation into study. Oral, injectable or implant hormonal contraceptives measure are not permitted.
9. A World Health Organization (WHO) performance status of 0 or 1 (Karnofsky ≥ 80)
10. Age \> 18 years.
11. Absence of metastases disease
12. Baseline Electrocardiography (EKG) 12 weeks prior to randomization. Baseline left ventricular ejection fraction (LVEF) value within limit of normal value for the institution or \> 50% of basal value
13. Normal laboratory test 2 weeks prior to randomization:
Haematology values: Neutrophil count ≥ 1,5 x109/l; Platelets ≥ 100 x 109/l; Haemoglobin ≥ 10mg/dl Biochemistry values: serum total bilirubin ≤ 1 x Upper Limit of Normal (ULN); Aspartate aminotransferase (AST) (SGOT) and Alanine aminotransferase (ALT) (SGPT) ≤ 2,5 x ULN; alkaline phosphatase ≤ 5 x ULN. Patients which AST and/or ALT value are \> 1,5 x ULN along with alkaline phosphatase value \> 2,5 x ULN will be not included into the study.
Renal function: serum creatinine ≤ 175 µmol/l (2 mg/dl). If the value is borderline, clearance creatinine must be ≥ 60 ml/min
14. 12 weeks prior to randomization the following assessments and procedures must be fulfilled: Bilateral mammography; Magnetic resonance imaging (MRI) Breast and axillary; Chest X-Ray (posterioanterior and lateral); Abdominal ultrasound; Chest CT-Scan; Abdominal CT-Scan. Bone Scan (if applicable)
15. Patients must be accessible for treatment and follow up
Exclusion Criteria
1. Patients with lumpectomy, partial mastectomy, modified radical mastectomy are not allowed to include into study.
2. Prior Immunotherapy, hormonal therapy and chemotherapy for breast cancer is not allowed.
3. Prior therapy with anthracycline and taxanes (paclitaxel and docetaxel) is not permitted for any neoplasia.
4. Prior radiotherapy for breast cancer.
5. Bilateral invasive breast carcinoma
6. Pregnant or nursing patients. Negative pregnant test (serum or urine) 14 days prior to randomization.
7. HER 2 negative breast cancer
8. Patients of childbearing potential must be use adequate contraceptive measures during study treatment. No hormonal contraceptive measure is permitted.
9. Any M1 breast cancer
10. Any motor or sensorial neurotoxicity grade ≥ 2 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.
11. Serious cardiac illness or medical conditions: Congestive heart failure, angina pectoris requiring specific treatment, myocardial infarction 1 year prior to enroll in the study; poorly controlled hypertension or high-risk uncontrolled arrhythmias.
History of significative neurological or psychiatric disease (psychotic, dementia or attack) what is unable to patient to grant her informed consent.
Uncontrolled severe Infection Uncontrolled diabetes mellitus, active peptic ulcer
12. Current malignancy or previous malignancy other that breast cancer. Exception cell carcinoma of the skin no melanoma, carcinoma in situ of the cervix or any other cancer in the past 10 years.
13. Long term treatment with corticoids except 6 months prior to inclusion in the study and low doses (≤ 20 mg methylprednisolone or equivalent)
14. Corticoid use contraindication
15. Concomitant hormonal replacement therapy. Previous treatment should be interrupted before inclusion into study.
16. Cardiopathy what stops patient taking Docetaxel and Trastuzumab: myocardial infarction recorded; angina pectoris requiring specific treatment; any congestive heart failure recorded; arrhythmia grade 3 or 4 according to NCI CTCAE version 3; any relevant valvular disease; chest X ray which shows cardiomegaly or EKG which shows ventricular hypertrophy unless LVEF value has been ≥ lower normal limit in the last 3 months.
17. Poorly controlled hypertension (systolic \> 180 mm Hg or diastolic \> 100 mm Hg). The patients with controlled hypertension under treatment can be included into study
18. Patients under treatment of arrhythmia, angina or congestive heart failure with drug which modifies cardiac conduction (after digital, beta blocker or inhibitors calcium channel) are excluded. However if these drugs are took for arterial tension the patient can be included into study.
19. The patient must interrupt concomitant treatment with hormonal therapy ej. raloxifene, tamoxifen and selective estrogen receptor modulators (SERM) prior to randomization.
20. Concomitant use of inhibitors and inductors of enzyme CYP3A4 complex (ketoconazole, itraconazole or grape juice; rifampicin, carbamazepin or fenitoin) are not permitted. Also, drug are substrate of enzyme CYP2C8 complex is not permitted along with lapatinib treatment.
21. Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial within 30 days prior to randomization into study.
22. Concomitant treatment with other anticancer therapy
23. Hypersensitivity reaction to drugs trastuzumab, lapatinib or their excipients.
24. Male
2. Prior Immunotherapy, hormonal therapy and chemotherapy for breast cancer is not allowed.
3. Prior therapy with anthracycline and taxanes (paclitaxel and docetaxel) is not permitted for any neoplasia.
4. Prior radiotherapy for breast cancer.
5. Bilateral invasive breast carcinoma
6. Pregnant or nursing patients. Negative pregnant test (serum or urine) 14 days prior to randomization.
7. HER 2 negative breast cancer
8. Patients of childbearing potential must be use adequate contraceptive measures during study treatment. No hormonal contraceptive measure is permitted.
9. Any M1 breast cancer
10. Any motor or sensorial neurotoxicity grade ≥ 2 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.
11. Serious cardiac illness or medical conditions: Congestive heart failure, angina pectoris requiring specific treatment, myocardial infarction 1 year prior to enroll in the study; poorly controlled hypertension or high-risk uncontrolled arrhythmias.
History of significative neurological or psychiatric disease (psychotic, dementia or attack) what is unable to patient to grant her informed consent.
Uncontrolled severe Infection Uncontrolled diabetes mellitus, active peptic ulcer
12. Current malignancy or previous malignancy other that breast cancer. Exception cell carcinoma of the skin no melanoma, carcinoma in situ of the cervix or any other cancer in the past 10 years.
13. Long term treatment with corticoids except 6 months prior to inclusion in the study and low doses (≤ 20 mg methylprednisolone or equivalent)
14. Corticoid use contraindication
15. Concomitant hormonal replacement therapy. Previous treatment should be interrupted before inclusion into study.
16. Cardiopathy what stops patient taking Docetaxel and Trastuzumab: myocardial infarction recorded; angina pectoris requiring specific treatment; any congestive heart failure recorded; arrhythmia grade 3 or 4 according to NCI CTCAE version 3; any relevant valvular disease; chest X ray which shows cardiomegaly or EKG which shows ventricular hypertrophy unless LVEF value has been ≥ lower normal limit in the last 3 months.
17. Poorly controlled hypertension (systolic \> 180 mm Hg or diastolic \> 100 mm Hg). The patients with controlled hypertension under treatment can be included into study
18. Patients under treatment of arrhythmia, angina or congestive heart failure with drug which modifies cardiac conduction (after digital, beta blocker or inhibitors calcium channel) are excluded. However if these drugs are took for arterial tension the patient can be included into study.
19. The patient must interrupt concomitant treatment with hormonal therapy ej. raloxifene, tamoxifen and selective estrogen receptor modulators (SERM) prior to randomization.
20. Concomitant use of inhibitors and inductors of enzyme CYP3A4 complex (ketoconazole, itraconazole or grape juice; rifampicin, carbamazepin or fenitoin) are not permitted. Also, drug are substrate of enzyme CYP2C8 complex is not permitted along with lapatinib treatment.
21. Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial within 30 days prior to randomization into study.
22. Concomitant treatment with other anticancer therapy
23. Hypersensitivity reaction to drugs trastuzumab, lapatinib or their excipients.
24. Male
Minimum Eligible Age
18 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Sponsor Role
collaborator
Spanish Breast Cancer Research Group
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Hospital Clínico Universitario de Valencia
Study Director
Role: STUDY_DIRECTOR
Hospital Clínico Universitario Virgen de la Victoria
Study Director
Role: STUDY_DIRECTOR
Hospital del Mar
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Site Status
Hospital General de Granollers
Granollers, Barcelona, Spain
Site Status
Xarxa Asistencial de Manresa
Manresa, Barcelona, Spain
Site Status
Corporación Sanitaria Parc Taulí
Sabadell, Barcelona, Spain
Site Status
Hospital del Espíritu Santo
Santa Coloma de Gramenet, Barcelona, Spain
Site Status
Consorci Sanitari de Terrassa
Terrassa, Barcelona, Spain
Site Status
Hospital Mutua de Terrassa
Terrassa, Barcelona, Spain
Site Status
Onkologikoa
Donostia / San Sebastian, Guipuzcoa, Spain
Site Status
Hospital Xeral Cíes
Vigo, Pontevedra, Spain
Site Status
Hospital Central de Asturias
Oviedo, Principality of Asturias, Spain
Site Status
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
Site Status
Complejo Hospitalario Universitario A Coruña
A Coruña, , Spain
Site Status
Centro Oncológico de Galicia
A Coruña, , Spain
Site Status
Hospital del Mar
Barcelona, , Spain
Site Status
Hospital Clinic i Provincial
Barcelona, , Spain
Site Status
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Site Status
Hospital General Yagüe
Burgos, , Spain
Site Status
Complejo Hospitalario San Pedro de Alcántara
Cáceres, , Spain
Site Status
Complejo Hospitalario Universitario Reina Sofía
Córdoba, , Spain
Site Status
Complejo Hospitalario de Jaén
Jaén, , Spain
Site Status
Hospital Universitario de la Princesa
Madrid, , Spain
Site Status
Hospital Clínico Universitario Virgen de la Victoria
Málaga, , Spain
Site Status
Hospital Virgen de la Salud
Toledo, , Spain
Site Status
Hospital Universitario La Fe
Valencia, , Spain
Site Status
Hospital Clinico Universitario de Valencia
Valencia, , Spain
Site Status
Hospital Universitario Miguel Servet
Zaragoza, , Spain
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Spain
References
Explore related publications, articles, or registry entries linked to this study.
Alba E, Albanell J, de la Haba J, Barnadas A, Calvo L, Sanchez-Rovira P, Ramos M, Rojo F, Burgues O, Carrasco E, Caballero R, Porras I, Tibau A, Camara MC, Lluch A. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. Br J Cancer. 2014 Mar 4;110(5):1139-47. doi: 10.1038/bjc.2013.831. Epub 2014 Jan 23.
Reference Type
RESULT
Related Links
Access external resources that provide additional context or updates about the study.
http://www.geicam.org
Sponsor's website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-007031-13
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
GEICAM/2006-14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
NCT00429299
COMPLETED
PHASE2
Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer
NCT01104571
UNKNOWN
PHASE3
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883
RECRUITING
PHASE2
Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors
NCT02307227
COMPLETED
PHASE2
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
NCT00482391
COMPLETED
PHASE2
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
NCT02073487
COMPLETED
PHASE2
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
NCT00821886
COMPLETED
PHASE2
A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
NCT02748213
COMPLETED
PHASE2
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
NCT00398489
UNKNOWN
PHASE2
Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer
NCT01321775
UNKNOWN
PHASE2
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients
NCT00485979
COMPLETED
PHASE2
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
NCT00004067
COMPLETED
PHASE3
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00005970
COMPLETED
PHASE3
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
NCT03556358
COMPLETED
PHASE3
A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.
NCT01485926
COMPLETED
PHASE2
Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast Cancer
NCT00379015
COMPLETED
PHASE2
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
NCT01367028
COMPLETED
PHASE2
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
NCT01572038
COMPLETED
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
NCT01275677
COMPLETED
PHASE3
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
NCT00309556
COMPLETED
PHASE3
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00769470
COMPLETED
PHASE2
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
NCT03595592
ACTIVE_NOT_RECRUITING
PHASE3
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
NCT00270894
COMPLETED
PHASE2